Sustainability Investors Products Research & Development Company Contact
Sustainability
ESG Environment Social
Investors
Reasons to invest Share information News Reports Corporate governance Stock exchange notices
Products
Salmon protein hydrolysate Salmon oil Calcium bone powder Collagen peptides European webshops
Research & Development
Our research All research programs Studies
Company
About us Our technology Operations Management Board of directors
Contact
Management Sales Investor relations
Type and search

All notices

COMPLETED EXTRAORDINARY GENERAL MEETING AND APPROVED SUBSEQUENT OFFERING

11.11.2020

PROXY RIGHTS AT GENERAL MEETING

09.11.2020

THIRD QUARTER 2020 FINANCIAL REPORT

30.10.2020

NEW SHARE CAPITAL INCREASE REGISTERED

27.10.2020

MANDATORY NOTIFICATION OF TRADE

21.10.2020

NOTICE OF EXTRAORDINARY GENERAL MEETING

21.10.2020

HBC RECEIVES APPROVAL FROM HEALTH CANADA FOR QUALIFIED HEALTH CLAIMS FOCUSED ON MAINTAINING HEALTHY LEVELS OF FERRITIN AND HEMOGLOBIN AND THE BLOOD COMPONENTS REQUIRED FOR OXYGEN TRANSPORT

19.10.2020

Disclosure of large shareholding

16.10.2020

KEY INFORMATION RELATING TO THE SUBSEQUENT OFFERING

16.10.2020

PRIVATE PLACEMENT SUCCESSFULLY PLACED

16.10.2020

Previous
1 2
3
4 5 6
...
27
Next
Sustainability
ESG Environment Social
Investors
Reasons to invest Share information News Reports Corporate governance Stock exchange notices
Products
Salmon protein hydrolysate Salmon oil Calcium bone powder Collagen peptides European webshops
Research & Development
Our research All research programs Studies
Company
About us Our technology Operations Management Board of directors
Contact
Management Sales Investor relations

Copyright 2021 Hofseth BioCare ASA
Privacy cookies